Pfizer Inc. (NYSE:PFE) [Trend Analysis] moved down reacts as active mover, shares a loss -0.74% to traded at $33.65 and the percentage gap among open changing to regular change was -0.35%. ICU Medical Inc. (ICUI) together with Pfizer Inc. (PFE) released that they have entered into a definitive contract under which ICU Medical will takeover all of Pfizer’s global infusion therapy business, Hospira Infusion Systems, for $1 billion in cash and stock.
Pfizer will receive about $400 million in newly issued shares of ICU Medical ordinary stock and $600 million in cash from ICU Medical subject to customary adjustment for net working capital. Upon completion of the accord, Pfizer will own about 16.6 percent of ICU Medical.
The Hospira Infusion Systems business comprises IV pumps, solutions, and devices. The acquisition complements ICU Medical’s existing business by creating a firm that has a complete IV therapy product portfolio from solutions to pumps to non-dedicated infusion sets, and gives the firm a importantly improved global footprint and a platform for continued competitiveness and growth. The firm’s current ratio calculated as 1.40 for the most recent quarter. The firm past twelve months price to sales ratio was 3.91 and price to cash ratio remained 9.75. As far as the returns are concern, the return on equity was recorded as 10.90% and return on investment was 7.30% while its return on asset stayed at 4.20%. The firm has total debt to equity ratio measured as 0.70.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 0.46% to $45.40. Teva Pharmaceutical Industries Ltd. (TEVA), Celltrion Inc. and Celltrion Healthcare reported that they have entered into an exclusive alliance to commercialize two of Celltrion’s mAb biosame candidates in the U.S. and Canada. CT-P10 is a proposed mAb biosame to Rituxan (rituximab), which is used to treat patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis or RA, Wegener’s Granulomatosis and Microscopic Polyangiitis (MPA).
CT-P6 is a proposed mAb biosame to Herceptin (trastuzumab), which is used for the treatment of HER2-overexpressing breast cancer and for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Combined yearly net sales for Rituxan and Herceptin are about $6.5 billion in the U.S. and Canada. The share price of TEVA attracts active investors, as stock price of week volatility recorded 2.31%. The stock is going forward to its 52-week low with 1.79% and lagging behind from its 52-week high price with -30.47%.